Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash from Operations: 2016-2025

Historic Cash from Operations for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$91.4 million.

  • Ultragenyx Pharmaceutical's Cash from Operations fell 36.46% to -$91.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$445.7 million, marking a year-over-year decrease of 6.47%. This contributed to the annual value of -$414.2 million for FY2024, which is 12.77% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Cash from Operations stood at -$91.4 million, which was up 15.56% from -$108.3 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Cash from Operations high stood at -$54.3 million for Q4 2021, and its period low was -$190.7 million during Q1 2024.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Cash from Operations value was -$108.3 million (recorded in 2025), while the average stood at -$114.1 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first slumped by 174.82% in 2021, then skyrocketed by 43.16% in 2024.
  • Ultragenyx Pharmaceutical's Cash from Operations (Quarterly) stood at -$54.3 million in 2021, then crashed by 66.24% to -$90.3 million in 2022, then rose by 7.13% to -$83.9 million in 2023, then climbed by 5.25% to -$79.5 million in 2024, then crashed by 36.46% to -$91.4 million in 2025.
  • Its Cash from Operations was -$91.4 million in Q3 2025, compared to -$108.3 million in Q2 2025 and -$166.5 million in Q1 2025.